FDA to review safety of anemia drugs from Amgen and Johnson & Johnson
The Food and Drug Administration said Wednesday that it would review of the safety of the widely used anemia drugs sold by Amgen and Johnson & Johnson after another clinical trial suggested that high doses of one of the drugs might cause strokes.
Amgen Inc., a unit of Takeda Pharmaceutical Co. has been forced to suspend a late-stage trial of a very promising cancer drug.